FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

On December 14, the US Food and Drug Administration (FDA) approved belzutifan for patients with advanced renal cell carcinoma following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

For more information read the FDA announcement and the Merck announcement.

Posted 12/18/2023